• Organizations: Nacuity Pharmaceuticals
FDA grants Breakthrough Therapy Designation to Nacuity's RP tablets
Pipeline

FDA grants Breakthrough Therapy Designation to Nacuity's RP tablets

Third designation for NPI-001 follows recent positive 24-month data showing a 50% photoreceptor reduction after 2 years of daily dosing.
FDA grants Nacuity Pharmaceuticals Fast Track designation for RP tablets
Pipeline

FDA grants Nacuity Pharmaceuticals Fast Track designation for RP tablets

Preclinical data showed NPI-001 (N-acetylcysteine amide) preserved photoreceptor cells and functionality; therapy is in clinical trials for RP associated with Usher syndrome.
Nacuity moves forward with trial of intravitreal implant for cataract progression delay
Pipeline

Nacuity moves forward with trial of intravitreal implant for cataract progression delay

First cohort in proof-of-concept study is enrolling patients undergoing vitrectomy.
Target enrollment achieved in trial for RP associated with Usher syndrome
Pipeline

Target enrollment achieved in trial for RP associated with Usher syndrome

The phase 1/2 study is assessing NPI-001, developed to block oxidative stress associated with RP and other blinding eye diseases.